Elevated levels of tetraploid cervical cells in human papillomavirus- positive papanicolaou smears diagnosed as atypical squamous cells of undetermined significance

Cancer

Volumn 102, Issue 3, 2004, Pages 192-199

  Olaharski, Andrew J ^a   Eastmond, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aneuploidy; Atypical squamous cells of undetermined significance (ASCUS); Human papillomavirus (HPV); Numerical chromosomal aberrations; Tetraploidy

Indexed keywords

ANEUPLOIDY; ARTICLE; ATYPICAL SQUAMOUS CELL OF UNDERTERMINED SIGNIFICANCE; CARCINOGENESIS; CELL STRUCTURE; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL; TETRAPLOIDY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 3; DNA PROBES, HPV; DNA, VIRAL; EPITHELIAL CELLS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PLOIDIES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 2942696519     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20259     Document Type: Article

References (55)

1. Bonfiglio TA. Atypical squamous cells of undetermined significance: a continuing controversy. Cancer (Cancer Cytopathol). 2002;96:125-127.
2. Davey DD, Nielsen ML, Naryshkin S, Robb JA, Cohen T, Kline TS. Atypical squamous cells of undetermined significance. Current laboratory practices of participants in the College of American Pathologists Interlaboratory. Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 1996;120:440-444.
3. Eltabbakh GH, Lipman JN, Mount SL, Morgan A. Significance of atypical squamous cells of undetermined significance on ThinPrep Papanicolaou smears. Gynecol Oncol. 2000;79:44-49.
4. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med. 1996;334:1030-1038.
5. Haverkos H, Rohrer M, Pickworth W. The cause of invasive cervical cancer could be multifactorial. Biomed Pharmacother. 2000;54:54-59.
6. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91: 973-976.
7. Pitman MB, Cibas ES, Powers CN, Renshaw AA, Frable WJ. Reducing or eliminating use of the category of atypical squamous cells of undetermined significance decreases the diagnostic accuracy of the Papanicolaou smear. Cancer (Cancer Cytopathol). 2002;96:128-134.
8. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
9. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000;19:1-5.
10. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958-964.
11. Herrington CS. Do HPV-negative cervical carcinomas exist? - revisited. J Pathol. 1999;189:1-3.
12. International Agency for Research on Cancer. Human papillomaviruses. Volume 64. Lyon: International Agency for Research on Cancer, 1995.
13. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281: 1605-1610.
14. Bosch FX, De Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
15. Kaufman RH. Is there a role for human papillomavirus testing in clinical practice? Obstet Gynecol. 2001;98(5 Pt 1):724-725.
16. Herbst AL, Pickett KE, Follen M, Noller KL. The management of ASCUS cervical cytologic abnormalities and HPV testing: a cautionary note. Obstet Gynecol. 2001;98(5 Pt 1): 849-851.
17. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 1999;80:1306-1311.
18. Paraskevaidis E, Malamou-Mitsi V, Koliopoulos G, et al. Expanded cytological referral criteria for colposcopy in cervical screening: comparison with human papillomavirus testing. Gynecol Oncol. 2001;82:355-359.
19. Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. BMJ. 2001;322:893-894.
20. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14-19.
21. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001;358:1782-1783.
22. Solomon D. Chapter 14: role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr. 2003;31:97-101.
23. Heselmeyer K, Schrock E, du Manoir S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA. 1996;93:479-484.
24. Olaharski AJ, Guzmán P, Gonsebatt ME, Sotelo-Regil R, Eastmond DA. Characterization of the numerical chromosomal aberrations during cervical carcinogenesis using multiple probe fluorescence in situ hybridization in a Mexican population. Environ Mol Mutagen. 2003;41:196.
25. Segers P, Haesen S, Castelain P, et al. Study of numerical aberrations of chromosome 1 by fluorescent in situ hybridization and DNA content by densitometric analysis on (pre)-malignant cervical lesions. Histochem J. 1995;27:24-34.
26. Hanselaar AG, Vooijs GP, Mayall BH, Pahlplatz MM, Van't Hof-Grootenboer AE. DNA changes in progressive cervical intraepithelial neoplasia. Anal Cell Pathol. 1992;4:315-324.
27. Bulten J, Poddighe PJ, Robben JC, Gemmink JH, de Wilde PC, Hanselaar AG. Interphase cytogenetic analysis of cervical intraepithelial neoplasia. Am J Pathol. 1998;152:495-503.
28. Atkin NB, Baker MC, Fox MF. Chromosome changes in 43 carcinomas of the cervix uteri. Cancer Genet Cytogenet. 1990; 44:229-241.
29. Reid R, Fu YS, Herschman BR, et al. Genital warts and cervical cancer. VI. The relationship between aneuploid and polyploid cervical lesions. Am J Obstet Gynecol. 1984;150: 189-199.
30. Kirkland JA, Stanley MA, Cellier KM. Comparative study of histologic and chromosomal abnormalities in cervical neoplasia. Cancer. 1967;20:1934-1952.
31. Southern SA, Evans MF, Herrington CS. Basal cell tetrasomy in low-grade cervical squamous intraepithelial lesions infected with high-risk human papillomaviruses. Cancer Res. 1997;57:4210-4213.
32. Giannoudis A, Evans MF, Southern SA, Herrington CS. Basal keratinocyte tetrasomy in low-grade squamous intra-epithelial lesions of the cervix is restricted to high and intermediate risk HPV infection but is not type-specific. Br J Cancer. 2000;82:424-428.
33. Bollmann R, Mehes G, Torka R, Speich N, Schmitt C, Bollmann M. Human papillomavirus typing and DNA ploidy determination of squamous intraepithelial lesions in liquid-based cytologic samples. Cancer. 2003;99:57-62.
34. Southern SA, Noya F, Meyers C, Broker TR, Chow LT, Herrington CS. Tetrasomy is induced by human papillomavirus type 18 E7 gene expression in keratinocyte raft cultures. Cancer Res. 2001;61:4858-4863.
35. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997;11:2090-2100.
36. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997;11: 2101-2111.
37. Zwerschke W, Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res. 2000;78:1-29.
38. Ishiji T. Molecular mechanism of carcinogenesis by human papillomavirus-16. J Dermatol. 2000;27:73-86.
39. Eastmond DA, Rupa DS, Hasegawa LS. Detection of hyperdiploidy and chromosome breakage in interphase human lymphocytes following exposure to the benzene metabolite hydroquinone using multicolor fluorescence in situ hybridization with DNA probes. Mutat Res. 1994;322:9-20.
40. Eastmond DA, Schuler M, Rupa DS. Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Mutat Res. 1995;348:153-162.
41. Bauer HM, Greer CE, Manos MM. Determination of genital human papillomavirus infection by consensus PCR amplification. In: Herrington CS, editor. Diagnostic molecular pathology: a practical approach. Oxford: Oxford University Press, 1992:131-152.
42. Sahai H, Khurshid A. In: Hercher RT, editor. Pocket dictionary of statistics. New York: McGraw-Hill Higher Education, 2002:43.
43. Ewers SB, Langstrom E, Baldetorp B, Killander D. Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry. 1984;5:408-419.
44. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer. 1988;61:334-339.
45. Wijkstrom H, Granberg-Ohman I, Tribukait B. Chromosomal and DNA patterns in transitional cell bladder carcinoma. A comparative cytogenetic and flow-cytofluorometric DNA study. Cancer. 1984;53:1718-1723.
46. Barrett MT, Pritchard D, Palanca-Wessels C, Anderson J, Reid BJ, Rabinovitch PS. Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. Cancer Res. 2003;63:4211-4217.
47. Shackney SE, Smith CA, Miller BW, et al. Model for the genetic evolution of human solid tumors. Cancer Res. 1989; 49:3344-3354.
48. Atkin NB, Baker MC. Nonrandom chromosome changes in carcinoma of the cervix uteri. II. Ten tumors in the triploid-tetraploid range. Cancer Genet Cytogenet. 1984;13:189-207.
49. Jakobsen A. Ploidy level and short-time prognosis of early cervix cancer. Radiother Oncol. 1984;1:271-275.
50. Kenter GG, Cornelisse CJ, Aartsen EJ, et al. DNA ploidy level as prognostic factor in low stage carcinoma of the uterine cervix. Gynecol Oncol. 1990;39:181-185.
51. Nguyen HN, Sevin BU, Averette HE, et al. The role of DNA index as a prognostic factor in early cervical carcinoma. Gynecol Oncol. 1993;50:54-59.
52. Nemec E, Van de Putte S, Van Pachterbeke C, et al. Ploidy and chromatin pattern analysis as an aid for cervical smear diagnosis. Histol Histopathol. 2002;17:403-409.
53. Lorenzato M, Bory JP, Cucherousset J, et al. Usefulness of DNA ploidy measurement on liquid-based smears showing conflicting results between cytology and high-risk human papillomavirus typing. Am J Clin Pathol. 2002;118:708-713.
54. Melsheimer P, Klaes R, Doeberitz MV, Bastert G. Prospective clinical study comparing DNA flow cytometry and HPV typing as predictive tests for persistence and progression of CIN I/II. Cytometry. 2001;46:166-171.
55. Bollmann R, Mehes G, Torka R, Speich N, Schmitt C, Bollmann M. Determination of features indicating progression in atypical squamous cells with undetermined significance: human papillomavirus typing and DNA ploidy analysis from liquid-based cytologic samples. Cancer (Cancer Cytopathol). 2003;99:113-117.